SeaStar Medical Holding Corporation (ICU) Key Metrics
ICU valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $15.3M
- Enterprise value
- $8.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 8.9
- Price / book
- 3.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −1.07
ICU key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsICU returns How much profit the business earns on the capital it uses.
ICU financial health Debt, liquidity and how easily interest is covered.
ICU efficiency & capital use Working capital cycle and where the cash goes.
ICU valuation history
ICU returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ICU debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ICU price vs earnings per share
ICU key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $49.8M | — | — | — | — | — |
| Enterprise value | $38.3M | — | — | — | — | — |
| Price / sales | 40.3 | — | — | — | — | — |
| Price / book | 4.8 | — | — | — | — | — |
| EV / sales | 31.0 | — | — | — | — | — |
| Earnings yield | −24.4% | — | — | — | — | — |
| Free cash flow yield | −27.3% | — | — | — | — | — |
| Share price at fiscal year-end | $2.40 | $19.40 | $110.75 | $1,025.00 | $2,510.00 | — |
| Per share | ||||||
| Revenue per share | $0.06 | — | — | — | — | — |
| Earnings per share | −$0.59 | — | — | — | — | — |
| Operating cash flow per share | −$0.66 | — | — | — | — | — |
| Free cash flow per share | −$0.66 | — | — | — | — | — |
| Cash per share | $0.58 | — | — | — | — | — |
| Book value per share | $0.50 | — | — | — | — | — |
| Tangible book value per share | $0.50 | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — |
| Debt per share | $0.03 | — | — | — | — | — |
| Shares outstanding | 20.7M | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −295.2% | — | — | — | — | — |
| Return on assets (ROA) | −129.1% | −607.8% | −800.9% | — | −261.7% | −112.6% |
| Return on tangible assets | −85.8% | −533.1% | −746.7% | −757.5% | −762.2% | −112.6% |
| Financial health | ||||||
| Total debt | $525,000 | $574,000 | $9.1M | $8.8M | $2.6M | $83,000 |
| Cash & short-term investments | $12.0M | $1.8M | $176,000 | $47,000 | $510,000 | $2.8M |
| Net debt | −$11.5M | −$1.2M | $8.9M | $8.8M | $2.1M | −$2.7M |
| Debt / equity | 0.05 | — | — | — | — | — |
| Debt / assets | 0.04 | 0.12 | 2.58 | 2.91 | 4.35 | 0.03 |
| Current ratio | 3.63 | 0.55 | 0.18 | 0.09 | 0.19 | 2.69 |
| Quick ratio | 3.61 | 0.55 | 0.18 | 0.09 | 0.19 | 2.64 |
| Interest coverage | -37.0 | -73.1 | -13.1 | -18.4 | -21.0 | -2.0 |
| Working capital | $9.8M | −$3.1M | −$10.7M | −$14.6M | −$2.5M | $1.8M |
| Invested capital | −$1.0M | −$3.4M | −$5.0M | −$12.0M | −$704,000 | −$74.3M |
| Tangible asset value | $10.4M | −$2.2M | −$13.9M | −$20.8M | −$2.8M | −$71.6M |
| Net current asset value | $9.8M | −$3.1M | −$15.1M | −$22.3M | −$2.8M | −$71.6M |
| Graham net-net per share | $0.41 | — | — | — | — | — |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 0.0% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 50.6% | 657.0% | — | — | — | — |
| R&D / revenue | 609.2% | 6,744.4% | — | — | — | — |
| SG&A / revenue | 473.1% | 6,595.6% | — | — | — | — |
| Efficiency | ||||||
| Days sales outstanding | 51.6 | 151.4 | — | — | — | — |
| Days of inventory on hand | 227.3 | — | — | — | — | — |
| Days payables outstanding | 13,752.9 | — | — | — | — | — |
| Cash conversion cycle (days) | -13,474.0 | — | — | — | — | — |
| Receivables turnover | 7.07 | 2.41 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.03 | 0.00 | 0.00 | — | — | — |
| Inventory turnover | 1.61 | — | — | — | — | — |
| Asset turnover | 0.13 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $174,500 | $56,000 | $6,000 | $35,000 | $51,478 | $44,955 |
| Average payables | $2.0M | $3.7M | $3.1M | $1.0M | $233,500 | $382,000 |
| Average inventory | $33,000 | $0 | — | — | $27,500 | $55,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ICU's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ICU valuation and financial ratios
SeaStar Medical earned a return on equity of −295.2% in fiscal 2025. It ended the year with $0.5 million of debt and $12.0 million in cash and short-term investments, a net cash position of $11.5 million.
See the ICU income statement, the ICU chart for price history, or the ICU stock overview for the latest quote and news.
ICU key metrics FAQ
What is SeaStar Medical's return on equity?
SeaStar Medical's return on equity (ROE) was −295.2% in fiscal 2025: net income of -$12.2 million on average shareholders' equity of $4.1 million.
How much debt does SeaStar Medical have?
SeaStar Medical had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is SeaStar Medical's free cash flow yield?
SeaStar Medical generated -$13.6 million of free cash flow in fiscal 2025, a free cash flow yield of −27.3% on its market value at year-end ($49.8 million).
What is SeaStar Medical's current ratio?
SeaStar Medical's current ratio was 3.63 at the end of fiscal 2025: current assets were 3.63 times current liabilities.